Start › Niedrobnokomórkowy rak płuca › Teksas › Houston
Badania kliniczne dla Niedrobnokomórkowy rak płuca w mieście Houston, TX
26 badań dla Niedrobnokomórkowy rak płuca szuka uczestników w ośrodkach w mieście Houston i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
RekrutacjaFaza 2
- The University of Texas MD Anderson Cancer Center /ID# 277929, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- MD Anderson Cancer Center, Houston
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RekrutacjaFaza 2/3
- Texas Oncology - Gulf Coast, Houston
- Texas Oncology - Gulf Coast, Houston
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
RekrutacjaFaza 3
- The University of Texas MD Anderson Cancer Center /ID# 280070, Houston
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RekrutacjaFaza 1/2
- Next Oncology - Houston, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekrutacjaFaza 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Site 1005, Houston
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
RekrutacjaFaza 1/2
- MD Anderson Cancer Center, Houston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RekrutacjaFaza 1/2
- Avenzo Therapeutics Recruiting Site, Houston
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
RekrutacjaFaza 3
- The University of Texas MD Anderson Cancer Center, Houston
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
RekrutacjaFaza 1/2
- MD Anderson Cancer Center Uni of Te, Houston
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
RekrutacjaFaza 1/2
- MD Anderson Cancer Center, Houston
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RekrutacjaFaza 3
- Houston Methodist Cancer Center, Houston
- University of Texas Md Anderson Cancer Center, Houston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
- Oncology Consultants, PA- Houston, Houston
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
RekrutacjaFaza 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of LY4175408 in Participants With Advanced Cancer
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
RekrutacjaFaza 2
- M D Anderson Cancer Center, Houston
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
RekrutacjaFaza 1/2
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
RekrutacjaFaza 1
- Zelgen Site 106, Houston
Badania dla Niedrobnokomórkowy rak płuca w innych miastach
- Arlington, VA23 badań
- Boston, MA21 badań
- New York City, NY21 badań
- Nashville, TN20 badań
- Los Angeles, CA20 badań
- Orlando, FL15 badań
- Dallas, TX13 badań
- St. Louis, MO13 badań
- Cleveland, OH13 badań
- Detroit, MI12 badań
- Chicago, IL12 badań
- Washington, DC12 badań
Inne badania w mieście Houston
- Niedrobnokomórkowy rak płuca145 badań
- Rak piersi126 badań
- Nowotwory (wszystkie typy)121 badań
- Nowotwór przerzutowy104 badań
- Rak jelita grubego i odbytnicy102 badań
- Rak jajnika89 badań
- Ostra białaczka szpikowa85 badań
- Rak płuc78 badań
- Rak prostaty76 badań
- Rak endometrium68 badań
- Rak trzustki61 badań
- Czerniak59 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.